.png)
14 Years of Excellence: South Korea’s Biggest Biologics Manufacturing Conference
17 - 18 September 2026
Songdo Convensia, Incheon, South Korea
Co-located Events
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
Silver
Bronze
EXHIBITION & NETWORKING
.jpg)
Associate
2026 SPEAKERS
Jong Gu Kim
Director, Quality
Lotte Biologics
South Korea
Kihyun Park, Ph.D.
Lead Scientist in AAV Process Discovery Part
Samsung Biologics
South Korea
Dae Won Kim, Ph.D.
Chief Executive Officer & Founder
ICM Co., Ltd.
South Korea
Paul Y. Song
Chief Executive Officer
NKGen Biotech
United States
Heechung Kwon
Chief Executive Officer
GencellMed
South Korea
Sammi Hsu
Senior Manager
Ever Supreme Biotechnology
Taiwan
Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas
CEO, Cellafa Biosciences
Japan
Cheng Yi (Jerry) Kuo
Assistant General Manager
UWell Biopharma
Taiwan
Young Jun Seo
CEO
Elonova
South Korea
Prof., Dr. Lee, Beom-Jin
Professor
Ajou University
South Korea
Chen Hong Hang
Global Solution Architect, Life Science Segment
Schneider Electric
Singapore
Eric Bishop
VP of Research and Development
Cygnus Technologies
United States
Hemasunder Reddy
Business Development Director
Pfanstiehl, Inc.
United States
Yo Kyung Chung
CTO and Head of R&D
Rophibio
South Korea
Doo Young Jung
Chief Executive Officer
PinotBio
South Korea
Yo-Sup Rew
Chief Technology Officer
Intocell
South Korea
Wei Han Lee
Director CMC
OBI Pharma
Taiwan
Won Gyun Ahn
Associate Director
Qurient
South Korea
Chung Yi Wu
CEO
CHO Pharma
Taiwan
Dr. John Luk
CEO & Founder
ArbeleBio
United States
Wei Ting Sun
Director R&D
HoneyBear Bioscience
Taiwan
Akshaya Bansal
Executive Director, ADC Platforms
Hummingbird Bioscience
Singapore
Heon Chang Lim
Director, Formulation
Samsung Biologics
South Korea
Yi Yang
CEO & Founder
Glyco-therapy Biotech
China
Giorgio Salciarini
Head of Sales - Technical Business Development
BSP Pharmaceuticals
Shawn Seong
CEO & Founder
Shaperon
South Korea
Agenda At A Glance
CONFERENCE DAY 1 | 17 September 2026 |
CONFERENCE DAY 2 | 18 September 2026 |
|||
|
|
|
|
|
|
|
Leadership Panel Discussion
Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
|
Redefining ADC Therapeutics
Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
|
|||
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Quality, Scale-Up & CMC Excellence
Bridging Development and Commercialisation
|
Discovery
Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
|
CAR-T & CAR-NK Therapies Case Studies
Next-Gen Cell Therapy & Preclinical Innovation
|
Advancing Payloads and Linker Technologies for Next-Generation ADCs
|
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Case Studies in Advanced Modalities
|
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
|
Advancing Gene Therapy
Optimizing Vectors, Editing Technologies, and Smart Manufacturing
|
||
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | ||||
|
Closing Roundtable Session
From Design to Delivery: Quality, CMC, and Clinical Insights Shaping the Next Wave of Biologics
|
Closing Roundtable Discussion
Next-Generation Modalities: Advancing Cell Therapy, Gene Therapy, and ADCs from Bench to Market
|
|||
| End of Conference Day 1 | ||||
CONFERENCE DAY 1 | 17 September 2026 | |
|
|
|
|
Leadership Panel Discussion
Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
|
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Quality, Scale-Up & CMC Excellence
Bridging Development and Commercialisation
|
Discovery
Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Case Studies in Advanced Modalities
|
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Closing Roundtable Session
From Design to Delivery: Quality, CMC, and Clinical Insights Shaping the Next Wave of Biologics
|
|
| End of Conference Day 1 | |
CONFERENCE DAY 2 | 18 September 2026 | |
|
|
|
|
Redefining ADC Therapeutics
Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
|
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
CAR-T & CAR-NK Therapies Case Studies
Next-Gen Cell Therapy & Preclinical Innovation
|
Advancing Payloads and Linker Technologies for Next-Generation ADCs
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Advancing Gene Therapy
Optimizing Vectors, Editing Technologies, and Smart Manufacturing
|
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Closing Roundtable Discussion
Next-Generation Modalities: Advancing Cell Therapy, Gene Therapy, and ADCs from Bench to Market
|
|
| End of Conference | |
CONFERENCE AGENDA
Day 1
Thursday, 17 September 2026
Biologics Manufacturing Korea 2026
ADC & Bioconjugate East Asia 2026
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
.png)
Leadership Panel Discussion: Scaling Biologics, ADC & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
9:00
Leadership Panel Discussion: Scaling Biologics, ADC & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
- Regional capacity expansion strategies and investment priorities
- Overcoming talent shortages, tech transfer challenges, and cost pressures
- Role of CDMOs, partnerships, and government collaboration
- Outlook for biologics, ADC and CGT manufacturing at scale
PANELISTS
Shawn Seong
CEO & Founder, Shaperon
Heon Chang Lim
Director, Formulation, Samsung Biologics
9:40
Arginine-Glutamate as Ideal Excipient for High Concentration Monoclonal Antibody Formulation.
- Need for higher dose of monoclonal antibodies(mAb) formulations
- Arginine-Glutamate a promising candidate to address concerns of aggregation, viscosity, liquid-liquid phase separation and longer storage
- Mechanism driving mAb stability in formulation containing Arginine-Glutamate
Hemasunder Reddy
Business Development Director, Pfanstiehl, Inc.
10:05
Fatty Acid-conjugated "Fattigation" Biomaterials for Improved Physicochemical and Biological Performance
- Fattigation-Fatty acid conjugation
- Synergistic drug delivery strategies
- Redox-sensitive fattigated hyaluronic acid nanoparticles
- Receptor-oriented cancer targeting
Prof., Dr. Lee, Beom-Jin
Professor, Ajou University
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Quality, Scale-Up & CMC Excellence: Bridging Development and Commercialisation
Discovery: Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
SESSION CHAIR
Yi Yang
CEO & Founder, Glyco-therapy Biotech
11:15
Data Integrity 2.0 (Strategic Quality Management and Integrated Lifecycle Collaboration, MAH - CDMO - Suppliers)
- The 2026 Regulatory Paradigm Shift
- Building an Honest Orgnizational Foundation from Quality Culture and Metrics perspective
- Lifecycle Collaboration Model between MAH - CDMO – Supplier
- Roadmap to 2026 and beyond
Jong Gu Kim
Director, Quality, Lotte Biologics
11:15
Engineering Next-Generation ADCs through Glycosite-Specific Glycan Design(TBC)
- Engineering glycan structures to improve ADC potency, stability, and therapeutic index.
- Modulating Fc biology to reduce off-target toxicity while preserving antitumor efficacy.
- Enabling homogeneous bispecific, dual-payload, and next-generation antibody conjugates.
- Translating glycosite-specific conjugation into scalable CMC and manufacturing advantages.
Reserved for Chung Yi Wu
CEO, CHO Pharma
11:40
Building the Digital Foundation for Scalable Biopharma Manufacturing: Unified Operations for Resilience, Compliance, and Efficiency
- Biologics and pharmaceutical manufacturers face increasing pressure to improve operational efficiency, compliance, resilience, and scalability. However, many facilities still rely on fragmented building, utility, and power systems that create silos and limit visibility.
- This talk explores how unified, AI-powered operations can provide a smarter digital foundation for biopharma manufacturing.
- Using Schneider Electric’s EcoStruxure Foresight as an example, the session will show how connected facility operations can improve uptime, streamline lifecycle management, support controlled environments, and enable more future-ready, data-driven operations.
Chen Hong Hang
Global Solution Architect, Life Science Segment, Schneider Electric
11:40
Supporting ADC From IND To The Long Term Commercial Supply: A Step Ahead Against The Challenges Of The Bioconjugates
- Serving the Innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Driving ADC Success with Flexible & High-Quality Solutions from Preclinical to Commercial
- Highlights on the approach to support early stage program through robust development studies.
- Ensuring right first-time-approved regulatory submission to save time and costs.
Giorgio Salciarini
Head of Sales - Technical Business Development, BSP Pharmaceuticals
11:55
Biosimilar Manufacturing: Integrated CMC Strategies for Global Development and Regulatory Access
- Evolving Biosimilar Market and Regulatory Environment
- Designing Analytical Similarity and CMC as One Integrated Strategy
- Managing Biosimilarity and Comparability from Development through Commercial Manufacturing
- Manufacturing Competitiveness: CoGS, Quality, and Supply Reliability
Reserved for Yo Kyung Chung
CTO and Head of R&D, Rophibio
12:05
PdRaxane: A NanoMab Drug Conjugate Addressing the Limitations of Classical ADCs
- Active tumor routing and retention through gp60, SPARC and PD-L1 targeting
- Non-covalent NanoMab assembly overcoming conventional conjugation and linker limitations
- Preclinical data show similar activity at 1/10 the dose — a dose-dependent reduction in toxicity that favors long-term therapy
- Integrated checkpoint blockade and nab-paclitaxel delivery remodels the immunosuppressive TME into a hot phenotype with increased effector T-cell activation
Shawn Seong
CEO & Founder, Shaperon
12:20
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
12:30
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Case Studies in Advanced Modalities
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
1:45
Chemical Engineering of Next-Generation mRNA Platforms for RNA Therapeutics
- Innovative chemical engineering of mRNA to enhance stability, translation efficiency, and therapeutic performance
- Next-generation mRNA platform technologies beyond vaccines
- Expanding RNA therapeutics for oncology, autoimmune diseases, and other therapeutic applications
- Future opportunities for collaboration in next-generation RNA medicines across Asia
Young Jun Seo
CEO, Elonova
1:45
From Site-Specific Conjugation to Dual-Payload ADCs: Enzymatic Strategies for Next-Generation Antibody Therapeutics
- Harnessing enzymatic glycan remodeling for precise antibody conjugation.
- Controlling conjugation sites and drug-to-antibody ratios.
- Stepwise conjugation strategies for dual-payload ADCs with tunable payload ratios.
- Expanding the design space of next-generation antibody conjugates.
Wei Ting Sun
Director R&D, HoneyBear Bioscience
2:10
Advanced Orthogonal Analysis of HCP using Mass Spectrometry
- Overview of Mass Spectrometry in HCP Analytics
- Advantages of MS in Coverage Analysis
- Identification of HCP in DS
- Relative and Absolute Quantification of individual HCPs using MS
Eric Bishop
VP of Research and Development, Cygnus Technologies
2:10
Expanding the Therapeutic Index and Overcoming Resistance via Glycan Conjugation
- Enhanced safety & infinite creation through YTConju®
- Enhanced efficacy through a novel TopoI
- Conquering resistance by synergistic dual-payload combinations
Yi Yang
CEO & Founder, Glyco-therapy Biotech
2:25
Enhancing AAV Manufacturing Yield Through a Promoter-Optimized Mini-Helper Plasmid
- Developed a Mini‑Helper plasmid - a minimized, promoter‑optimized helper plasmid retaining only essential AAV helper genes.
- Boosted AAV productivity — achieved 2.0–6.5× higher AAV titers depending on serotype, with reduced cost and no compromise in particle quality.
- Validated scalability — consistent performance from flask scale up to 2 L and 200 L bioreactors, demonstrating a scalable, cost‑effective AAV manufacturing solution.
Kihyun Park, Ph.D.
Lead Scientist in AAV Process Discovery Part, Samsung Biologics
2:35
Formulation / Lyophilization Case Study for ADC Molecules: Challenges and Breakthrough
- ADC
- Formulation
- Lyophilization
Heon Chang Lim
Director, Formulation, Samsung Biologics
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
3:30
Closing Roundtable Session: From Design to Delivery: Quality, CMC, and Clinical Insights Shaping the Next Wave of Biologics
-
Quality by Design vs. Quality by Inspection: Closing the Gap Between Theory and Practice
-
CMC Risk Management: Identifying and De-Risking Critical Process Parameters Early
-
CDMO Selection: Beyond Capacity: What Really Predicts a Successful Partnership?
-
Resistance Mechanisms and Sequencing ADCs in Treatment Paradigms
-
Managing On-Target Off-Tumor Toxicity in Early Development
-
Glycan Engineering for Improved ADC and Biologics Efficacy
4:30
Chairman Closing Remarks
4:35
End of Conference Day 1
CONFERENCE AGENDA
Day 2
Friday, 18 September 2026
Biologics Manufacturing Korea 2026
ADC & Bioconjugate East Asia 2026
8:50
IMAPAC's Opening Address
8:55
Chairman's Opening Address
Redefining ADC Therapeutics: Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
Exhibition Hall, Ballroom B
9:00
Integrating Enzymatic Glycan Conjugation, Scalable One-Pot Manufacturing, and Advanced Analytical Control Strategies for Mono- and Dual-Payload ADCs
- Overcoming the limitations of traditional random conjugation through site-specific glycan remodeling and innovative linker technologies.
- Transforming enzymatic conjugation into a cost-effective, highly robust, and industrially scalable manufacturing process.
- Establishing analytical foundations, DAR characterization, and control strategies for mono- and dual-payload ADCs.
Wei Han Lee
Director CMC, OBI Pharma
9:25
Beyond BsADCs: From Better Delivery to Checkmate Killing with Novel Proteasome Inhibitor Payload
- The ADC Evolution & The Lethality Gap
- The Next Wave: Overcoming Resistance
- Pioneering Novel Payloads (The QLi5 Platform)
Won Gyun Ahn
Associate Director, Qurient
9:50
OHPASTM, PMTTM, and NexatecanTM Technologies for Enhanced ADC Efficacy and Safety
- OHPASTM linker design and PMTTM mechanism
- Proprietary NexatecanTM and iso-NexatecanTM TOP1 inhibitor payloads
- Next-generation ADC development enabled by IntoCell’s platform
Yo-Sup Rew
Chief Technology Officer, Intocell
10:15
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B
CAR-T & CAR-NK Therapies Case Studies: Next-Gen Cell Therapy & Preclinical Innovation
SESSION CHAIR
Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences
Advancing Payloads and Linker Technologies for Next-Generation ADCs
11:00
ICM-203 AAV Gene Therapy as a Promising DMOAD Candidate for OA Treatment
- Target (Nkx3.2) discovery and validation for OA treatment
- Preclinical validation of ICM-203 for DMOAD activity
- First-in-human clinical development of ICM-203
Dae Won Kim, Ph.D.
Chief Executive Officer & Founder, ICM Co., Ltd.
11:00
Dual-Payload ADC Platform: Advancing Rational Payload Combinations to Address Resistance(TBC)
- Addressing ADC payload resistance through rationally selected dual-payload combinations.
- Integrating payload selection, conjugation strategy, linker chemistry, and antibody engineering to optimize efficacy and minimize off-target toxicity.
- Streamlining development and manufacturing to accelerate candidate-to-IND progression.
Akshaya Bansal
Executive Director, ADC Platforms, Hummingbird Bioscience
11:25
Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases
- Troculeucel’s mechanism of action in reducing CSF neuroinflammatory and protein biomarkers.
- Reviewing the early clinical efficacy of Troculeucel in AD, PD, and FTD patients.
- Discuss regulatory landscape in Asia to expedite development and commercialization of Troculeucel
Paul Y. Song
Chief Executive Officer, NKGen Biotech
11:25
Combining Payload Selection, Linker Design and Site-specific Conjugation for Dual Payload ADC Development
- Importance of payload selection for the design of dual payload ADC - pharmacology and physicochemical properties perspective
- Exploitation of novel linkers to expand the applicable payload scope
- Improving stability of dual payload ADCs by applying site-specific conjugation
Doo Young Jung
Chief Executive Officer, PinotBio
11:50
Driving Innovation in Cell Therapy Manufacturing with AI and Robotics: From Process Optimization to Regulatory-Ready Platforms
- Feasibility study results on AI-driven process optimization for iPSC-derived NK cell production, utilizing machine learning to analyze process data generated by the dual-arm LabDroid “Maholo” automation system.
- The discussion will cover how AI-enabled data analysis and robotic automation can improve yield, enhance batch-to-batch consistency, and support robust cell quality in advanced cell therapy manufacturing.
- Outline a regulatory strategy for implementing robotic automation in GMP environments, including key considerations from interactions with regulatory agencies.
Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences
12:15
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Advancing Gene Therapy: Optimizing Vectors, Editing Technologies, and Smart Manufacturing
Exhibition Hall, Ballroom A
SESSION CHAIR
Heechung Kwon
Chief Executive Officer, GencellMed
1:45
Advancing Allogeneic CAR-T for Solid Tumors: From Phase II Clinical Development to Next-Generation In Vivo CAR-T
- Clinical progress and Phase IIa development strategy of CAR001, an allogeneic off-the-shelf CAR-T therapy for solid tumors.
- Emerging clinical insights from recurrent glioblastoma and other solid tumor indications.
- Manufacturing and scalability considerations for next-generation allogeneic cell therapies.
- Leveraging clinical experience to develop EXO001, an in vivo CAR-T platform.
Sammi Hsu
Senior Manager, Ever Supreme Biotechnology
2:10
Clinical Development of CRA-T Cell Therapy: Manufacturing, Formulation and Administration.
Reserved for Cheng Yi (Jerry) Kuo
Assistant General Manager, UWell Biopharma
2:35
Development of an Oncolytic Gene Therapy for Peritoneal Cancer Using Retargeted HSV Vectors
- To strictly redirect oncolytic herpes simplex virus (oHSV) to cancer-specific antigens, Gencellmed developed the SMARTTM HSV retargeting platform, a novel, double-retargeted oHSV system.
- GencellMed's lead oncology asset GCM-101: Unlike conventional oHSVs that largely retain natural viral tropism, GCM-101 is engineered to exclusively enter EpCAM-expressing cancer cells, thereby maximizing tumor selectivity and minimizing off-target infection of normal cells.
- Preclinical evaluations of GCM-101’s broad therapeutic potential across solid tumors with high EpCAM expression, including ovarian, colorectal, gastric, pancreatic, and lung cancers.
Heechung Kwon
Chief Executive Officer, GencellMed
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Premier Ballroom A
3:30
Closing Roundtable Session - Navigating Complexity: Practical Solutions for Cell, Gene, and ADC Therapeutics in East Asia
-
Cell Therapy Clinical Development: What Works and What Doesn’t
Cheng Yi (Jerry) KuoAssistant General Manager, UWell Biopharma
-
Next-Gen Payload and Linker Innovation: What's Actually Moving the Needle Post-ADC 1.0
-
Beyond CAR-T: Overcoming Manufacturing and Access Bottlenecks in Solid Tumor Cell Therapies
Hideto YamaguchiSenior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences
-
Gene Editing vs. Gene Addition: How CRISPR-Based Approaches Are Reshaping the Field
-
Linker-Payload Conjugation Chemistry: Balancing DAR Control and Manufacturing Reproducibility
4:30
Chairman Closing Remarks
4:35
End of Conference
By Profile
By Job Title
By Geography
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
Our Past Partners
.png)
